

**STABILITY
OF DRUGS
AND
DOSAGE
FORMS**

**Sumie Yoshioka
and
Valentino J. Stella**

Stability of Drugs and Dosage Forms

Stability of Drugs and Dosage Forms

Sumie Yoshioka

*National Institute of Health Sciences
Tokyo, Japan*

and

Valentino J. Stella

*The University of Kansas
Lawrence, Kansas*

Kluwer Academic Publishers

New York, Boston, Dordrecht, London, Moscow

Opiant Exhibit 2301

Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.

IPR2019-00685, IPR2019-00688, IPR2019-00694

Page 3

eBook ISBN: 0-306-46829-8
Print ISBN: 0-306-46404-7

©2002 Kluwer Academic Publishers
New York, Boston, Dordrecht, London, Moscow

All rights reserved

No part of this eBook may be reproduced or transmitted in any form or by any means, electronic, mechanical, recording, or otherwise, without written consent from the Publisher

Created in the United States of America

Visit Kluwer Online at: <http://www.kluweronline.com>
and Kluwer's eBookstore at: <http://www.ebooks.kluweronline.com>

Contents

1. Introduction	1
2. Chemical Stability of Drug Substances	3
2.1. Pathways of Chemical Degradation	4
2.1.1. Hydrolysis	5
2.1.1.1. Esters	5
2.1.1.2. Amides	10
2.1.1.3. Barbiturates, Hydantoins, and Imides	12
2.1.1.4. Schiff Base and Other Reactions Involving Carbon–Nitrogen Bond Cleavage	15
2.1.1.5. OtherHydrolysisReactions	17
2.1.2. Dehydration	18
2.1.3. IsomerizationandRacemization	18
2.1.4. Decarboxylation and Elimination	22
2.1.5. Oxidation	24
2.1.6. Photodegradation	28
2.1.7. Drug–Excipientand Drug–Drug Interactions	29
2.1.7.1. Reactions of Bisulfite, an Antioxidant	30
2.1.7.2. Reaction of Amines with Reducing Sugars	30
2.1.7.3. Transesterification Reactions	33
2.2. Factors Affecting Chemical Stability	34
2.2.1. Basic Kinetic Principles	34
2.2.2. The Role of Molecular Structure	37
2.2.3. Rate Equations and Kinetic Models	38
2.2.3.1. Kinetic Models to Describe Drug Degradation in Solution	39
2.2.3.2. Kinetic Models Describing Chemical Drug Degradationin the Solid State	52
2.2.3.3. Calculation of Rate Constants by Fitting to Kinetic Models	61
2.2.4. Temperature	61
2.2.4.1. General Principles	61

vii

Opiant Exhibit 2301
Nalox-1 Pharmaceuticals, LLC v. Opiant Pharmaceuticals, Inc.
IPR2019-00685, IPR2019-00688, IPR2019-00694

Page 5

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.